How to buy Crinetics Pharmaceuticals stock

Crinetics Pharmaceuticals, Inc is a biotechnology business based in the US. Crinetics Pharmaceuticals shares (CRNX) are listed on the NASDAQ and all prices are listed in US Dollars. Crinetics Pharmaceuticals employs 93 staff and has a trailing 12-month revenue of around 0.00.

Crinetics Pharmaceuticals share price

Use our graph to track the performance of CRNX stocks over time.

Crinetics Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$11.61 - $23.70
50-day moving average	$16.60
200-day moving average	$14.94
Wall St. target price	$32.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.62

Buy Crinetics Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Crinetics Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Crinetics Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Crinetics Pharmaceuticals financials

Revenue TTM	$71,000
Gross profit TTM	$-56,927,000
Return on assets TTM	-29.86%
Return on equity TTM	-51.61%
Profit margin	0%
Book value	$5.12
Market capitalisation	$645.4 million

TTM: trailing 12 months

Shorting Crinetics Pharmaceuticals shares

There are currently 1.5 million Crinetics Pharmaceuticals shares held short by investors – that's known as Crinetics Pharmaceuticals's "short interest". This figure is 2.2% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Crinetics Pharmaceuticals shares can be evaluated.

Crinetics Pharmaceuticals's "short interest ratio" (SIR)

Crinetics Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Crinetics Pharmaceuticals shares currently shorted divided by the average quantity of Crinetics Pharmaceuticals shares traded daily (recently around 177929.64244521). Crinetics Pharmaceuticals's SIR currently stands at 8.67. In other words for every 100,000 Crinetics Pharmaceuticals shares traded daily on the market, roughly 8670 shares are currently held short.

However Crinetics Pharmaceuticals's short interest can also be evaluated against the total number of Crinetics Pharmaceuticals shares, or, against the total number of tradable Crinetics Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Crinetics Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Crinetics Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0538% of the tradable shares (for every 100,000 tradable Crinetics Pharmaceuticals shares, roughly 54 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Crinetics Pharmaceuticals.

Find out more about how you can short Crinetics Pharmaceuticals stock.

Crinetics Pharmaceuticals share dividends

We're not expecting Crinetics Pharmaceuticals to pay a dividend over the next 12 months.

Crinetics Pharmaceuticals share price volatility

Over the last 12 months, Crinetics Pharmaceuticals's shares have ranged in value from as little as $11.61 up to $23.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crinetics Pharmaceuticals's is 1.2212. This would suggest that Crinetics Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Crinetics Pharmaceuticals overview

Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California. .

Frequently asked questions

• What percentage of Crinetics Pharmaceuticals is owned by insiders or institutions?

  Currently 3.853% of Crinetics Pharmaceuticals shares are held by insiders and 89.286% by institutions.

• How many people work for Crinetics Pharmaceuticals?

  Latest data suggests 93 work at Crinetics Pharmaceuticals.

• When does the fiscal year end for Crinetics Pharmaceuticals?

  Crinetics Pharmaceuticals's fiscal year ends in December.

• Where is Crinetics Pharmaceuticals based?

  Crinetics Pharmaceuticals's address is: Building No. 2, San Diego, CA, United States, 92121

• What is Crinetics Pharmaceuticals's ISIN number?

  Crinetics Pharmaceuticals's international securities identification number is: US22663K1079

• What is Crinetics Pharmaceuticals's CUSIP number?

  Crinetics Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 22663K107